Kiniksa Pharmaceuticals Headquarters
Looking for information about Kiniksa Pharmaceuticals Headquarters? The links below have collected all the necessary data.
Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ; US Headquarters Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100; USA California Kiniksa Pharmaceuticals Corp. 9191 Towne Centre Drive, Suite 330 San Diego, CA 92122; Bermuda Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 ...
https://www.kiniksa.com/stay-informed
Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ; US Headquarters Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100; USA California Kiniksa Pharmaceuticals Corp. 9191 Towne Centre Drive, Suite 330 San Diego, CA 92122; Bermuda Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 ...
https://www.kiniksa.com/clinical-trials
Kiniksa Pharmaceuticals (UK), Ltd. Third Floor 23 Old Bond Street London, UK W1S 4PZ; US Headquarters Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue Lexington, MA 02421 USA (781) 431-9100; USA California Kiniksa Pharmaceuticals Corp. 9191 Towne Centre Drive, Suite 330 San Diego, CA 92122; Bermuda Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 ...
https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-outlines-next-steps-development-mavrilimumab
Jun 08, 2021 · HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today outlined next steps for the development of mavrilimumab, an investigational fully-human monoclonal antibody that …
https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-positive-results-mavrilimumab-phase-2-trial
Apr 12, 2021 · HAMILTON, Bermuda, April 12, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the Phase 2 portion of the Phase 2/3 trial of mavrilimumab in non-mechanically-ventilated patients (Cohort 1) with severe …
Have you found Kiniksa Pharmaceuticals Headquarters information?
On our site you can find many other information about headquarters of any company. Research information about other companies.
Related Pages:
|
Recently Added Pages:
|